LANSOPRAZOLE 30MG VERSUS OMEPRAZOLE 40MG IN THE TREATMENT OF REFLUX ESOPHAGITIS GRADE-II, GRADE-III AND GRADE-IVA (A DUTCH MULTICENTER TRIAL)

Objectives: To compare the efficacy and safety of lansoprazole 30 mg d aily (LAN30) and omeprazole 40 mg daily (OME40) in the treatment of mo derate (Savary-Miller grade II) as well as severe reflux oesophagitis (grade III/IVa). Design: A double-blind, randomized, multicentre study , involving 211 patients at 29 Dutch hospitals. Methods: Healing was a ssessed by endoscopy, performed on admission, after 4 weeks and after 8 weeks if the patient was not healed after 4 weeks. Symptom relief wa s determined by symptom assessments at the same time points. Safety wa s evaluated by determining the incidence of adverse events. Results: T here was no significant difference in intention-to-treat (ITT) healing rates after 4 weeks (LAN30 87.5%, OME40 80.6%; 95% CI (-4.0; +17.8)) and in the ITT overall healing (LAN30 96.1%, OME40 93.1%; 95% CI (-4.2 ; +10.2)) rates between the LAN30 and the OME40 group. Relief of reflu x-related symptoms at 4 weeks as well as 8 weeks did not differ signif icantly between the treatment groups. No difference in the incidence o f adverse events was observed between the groups. Conclusion: Treatmen t of patients with reflux oesophagitis grade II, III or IVa with LAN30 was as effective as with OME40 with respect to healing as well as sym ptom relief.